Treatment with Omalizumab in Psoriatic Patients
- Conditions
- Psoriasis.Psoriasis, unspecifiedL40.9
- Registration Number
- IRCT20150716023235N18
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Patients with mild to moderate psoriasis (with PASI more than 10-15 and less than 30-40) with more than 10-15% involvement and whose disease is not so mild and limited to respond to routine topical treatment (they have received routine topical treatment and have not reached the minimum acceptable therapeutic response*), And it was not so severe and extensive that needs severe stage treatments (with too many side effects). *Minimum acceptable therapeutic response: BSA less than 3% or BSA reduction greater than 75% (compared to the time of starting treatment) at 3 months after starting treatment.
Patients living in remote area who cannot travel a long distance to receive phototherapy 3 times a week and for a long period of time.
30-50 years old
Prior history of Omalizumab injection
Prior history of receiving systemic treatments for psoriasis such as Methotrexate, Ciclosporin, Acitretin, Etanercept, Adalimumab, Infliximab, and Ustekinumab.
Prior history of phototherapy
Past anaphylaxis history
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psoriasis Severity. Timepoint: At 5 timepoints, before, during and after intervention (month O, 1, 2, 4, and 6). Method of measurement: Psoriasis Area and Severity Index (PASI).
- Secondary Outcome Measures
Name Time Method Dermatology Life Quality. Timepoint: Before intervention and after 6 months of intervention. Method of measurement: Dermatology Life Quality Index; DLQI.;Serum Total IgE Level. Timepoint: Before intervention and after 6 months of intervention. Method of measurement: Elisa.